JNJ-37822681

DRUG2 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

Schizophrenia

Phase 2

An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia

CompletedNCT00728195

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Schizophrenia

Start: 2008-11-30End: 2010-02-28Updated: 2014-03-26

A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia

CompletedNCT01812642

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Schizophrenia

Start: 2008-07-31End: 2008-12-31Updated: 2014-03-18